🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesNNT for MACE prevention — 6 month update Page 2

NNT for MACE prevention — 6 month update

MikeNYC_runner Mon, Aug 25, 2025 at 1:57 AM 12 replies 1,433 viewsPage 2 of 3
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Aug 25, 2025 at 10:53 AM#6
Dr.SleepRoch said:
6 month update on cardiovascular risk: down 46 lbs, off blood pressure meds, A1C normalized.

Pushing back on Dr.SleepRoch here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

Last edited: Aug 25, 2025 at 12:53 PM
5 8Dr.NateNeph, PharmD_Rodriguez, julia.endo and 2 others
Reply Quote Save Share Report
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Aug 25, 2025 at 2:24 PM#7
MikeNYC_runner said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:

  • NT-proBNP: 58 pg/mL (normal, cardiac function preserved)
  • Lp(a): 58 nmol/L (genetic, unchanged — expected)
  • ApoB: dropped from 143 to 98 mg/dL (excellent response)
  • Coronary calcium score: 0 (unchanged from baseline — reassuring)

The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.

6 9tom_AK, josh_phd_bmore, roxy_nash and 3 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Aug 25, 2025 at 5:55 PM#8
LibrarianMeg said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

I'm 62 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

9 months later: down 56 lbs, off lisinopril, A1C from 7.2% to 5.5%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Aug 25, 2025 at 11:55 PM
7 10Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 4 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Aug 25, 2025 at 9:26 PM#9

Following on from EndoResFellow — and this may be the naive question:

How long did you give it before you decided it was working?

8 11MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 5 others
Reply Quote Save Share Report
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
Aug 26, 2025 at 2:19 PM#10
Dr.BariatricHTX said:
I'm 62 years old and want to share my perspective on cardiovascular risk as an older member of this community.

Dizziness and cardiovascular risk: I was lightheaded for the first 3 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

14 14MASHdoc_SA, GenomicsKate, Dr.ObesityMed and 11 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register